Cara Therapeutics Is A Biotechnology Company Based In Stamfordconnecticutdedicated To Developing Therapeutics For Chronic Pruritus And Pain Managementthe Company Focuses On Peripherally Acting Kappa Opioid Receptor Agonists To Meet The Medical Needs Of Patients Suffering From Itch Associated With Chronic Kidney Diseaseliver Diseaseand Atopic Dermatitis The Company S Flagship Productkorsuvadifelikefalin Is Fda Approved For Treating Moderate To Severe Pruritus In Adults Undergoing Hemodialysiskorsuva Injection Is A First In Class Treatment That Effectively Reduces Itch Without Central Nervous System Side Effectscara Therapeutics Is Also Exploring Oral Formulations Of Difelikefalin For Pruritus In Chronic Liver Disease And Atopic Dermatitisalong With Other Candidates For Neuropathic And Acute Pain Cara Therapeutics Primarily Serves Healthcare Providers And Patients In Nephrologyhepatologyand Dermatologythe Company Collaborates With Medical Institutions And Researchers To Advance Clinical Trials And Expand Its Therapeutic Applicationsaiming To Improve The Quality Of Life For Patients Dealing With Chronic Pruritus
